Prevention of neonatal group B streptococcus disease in the 21st century

Area of Science:

• Neonatal Health
• Infectious Disease Epidemiology
• Obstetrics & Gynecology

Background:

• Group B Streptococcus (GBS) remains a primary cause of neonatal sepsis in Australia and New Zealand.
• Intrapartum antibiotic prophylaxis (IAP) has reduced early-onset GBS disease but has altered the profile of affected infants.
• Preterm infants are particularly vulnerable to GBS-related morbidity and mortality.

Purpose of the Study:

• To provide an updated overview of GBS preventative management strategies in the perinatal period.
• To incorporate recent guidelines from the United States, Australia, and New Zealand.
• To highlight the ongoing challenges and evolving landscape of GBS prevention.

Main Methods:

• Review of current literature and epidemiological data on neonatal GBS disease.
• Analysis of the impact of maternal intrapartum antibiotic prophylaxis (IAP) policies.
• Comparison of universal screening-based versus risk-based assessment approaches for IAP.

Main Results:

• Universal screening in the US appears to yield lower early-onset GBS infection rates compared to risk-based assessments.
• Many infants developing early-onset GBS disease lack typical intrapartum risk factors or have negative maternal screens.
• IAP has shifted the characteristics of infants affected by early-onset GBS disease.

Conclusions:

• Clinicians must maintain vigilance for sepsis signs in all newborns, irrespective of known risk factors.
• Updated GBS preventative management strategies are crucial, considering international and regional guidelines.
• Ongoing evaluation of GBS screening and prophylaxis is essential to minimize neonatal morbidity and mortality.